2025-2031 Global HIV Vaccine Industry Research & Trends Analysis Report- YH Research

日本语 | 中文

Home > Reports >Pharma & Healthcare > 2025-2031 Global HIV Vaccine Industry Research & Trends Analysis Report

2025-2031 Global HIV Vaccine Industry Research & Trends Analysis Report

Publication Date: 2025-10-20
Report Id: 2559846
Industry: Pharma & Healthcare
Report Page: 121
Chart: 121

PDF Download

Publication Date: 2025-10-20
Report Id: 2559846
Industry: Pharma & Healthcare
Report Page: 121
Chart: 121

PDF Download

A research report provider that focuses on identifying industry pain points and solving core problems for companies！

Table of Contents
Description
Table of Figures
Need a Quote?

1 Market Overview
1.1 HIV Vaccine Definition
1.2 Global HIV Vaccine Market Size and Forecast
1.2.1 By Revenue, Global HIV Vaccine Market Size, 2020-2031
1.2.2 By Sales Volume, Global HIV Vaccine Market Size, 2020-2031
1.2.3 Global HIV Vaccine Price Trend, 2020-2031
1.3 China HIV Vaccine Market Size and Forecast
1.3.1 By Revenue, China HIV Vaccine Market Size, 2020-2031
1.3.2 By Sales Volume, China HIV Vaccine Market Size, 2020-2031
1.3.3 China HIV Vaccine Price Trend, 2020-2031
1.4 China Percentage in Global Market
1.4.1 By Revenue, China HIV Vaccine Share in Global Market, 2020-2031
1.4.2 By Sales Volume, China HIV Vaccine Share in Global Market, 2020-2031
1.4.3 HIV Vaccine Market Size: China VS Global, 2020-2031
1.5 HIV Vaccine Market Dynamics
1.5.1 HIV Vaccine Market Drivers
1.5.2 HIV Vaccine Market Restraints
1.5.3 HIV Vaccine Industry Trends
1.5.4 HIV Vaccine Industry Policy

2 Global Competitive Landscape by Company
2.1 Global HIV Vaccine Revenue by Company, 2020-2025
2.2 Global HIV Vaccine Sales Volume by Company, 2020-2025
2.3 Global HIV Vaccine Price by Company, 2020-2025
2.4 Global HIV Vaccine Participants, Market Position (Tier 1, Tier 2, and Tier 3)
2.5 Global HIV Vaccine Concentration Ratio
2.6 Global HIV Vaccine Mergers & Acquisitions, Expansion Plans
2.7 Global HIV Vaccine Manufacturers Product Type

3 China Competitive Landscape by Company
3.1 China HIV Vaccine Revenue by Company, 2020-2025
3.2 China HIV Vaccine Sales Volume by Company, 2020-2025
3.3 China HIV Vaccine HIV Vaccine Participants, Market Position (Tier 1, Tier 2, and Tier 3)
3.4 China HIV Vaccine Market, Sales Percentage of Local Players VS Foreign Players (2020-2025)
3.5 Chinese Local Players, HIV Vaccine Domestic VS Export
3.6 China Market, HIV Vaccine Import & Export
3.6.1 China Market, HIV Vaccine Import & Export, 2020-2031
3.6.2 China HIV Vaccine Import & Export Trends
3.6.3 Main Sources of China HIV Vaccine Import
3.6.4 Export Destination of China HIV Vaccine

4 HIV Vaccine Production by Region
4.1 Global HIV Vaccine Capacity, Production and Capacity Utilization, 2020-2031
4.2 Global Geographic Distribution of HIV Vaccine Manufacturers
4.3 Global Major Manufacturers, HIV Vaccine Capacity Expansion and Future Plans
4.4 Global HIV Vaccine Capacity by Region
4.5 Global HIV Vaccine Production by Region
4.5.1 Global HIV Vaccine Production & Forecast by Region, 2020 VS 2024 VS 2031
4.5.2 Global HIV Vaccine Production by Region, 2020-2025
4.5.3 Global HIV Vaccine Production Market Share & Forecast by Region, 2020-2031

5 Industry Chain Analysis
5.1 HIV Vaccine Industry Chain
5.2 HIV Vaccine Upstream Analysis
5.2.1 HIV Vaccine Core Raw Materials
5.2.2 Main Manufacturers of HIV Vaccine Core Raw Materials
5.3 Midstream Analysis
5.4 Downstream Analysis
5.5 HIV Vaccine Production Mode
5.6 HIV Vaccine Procurement Model
5.7 HIV Vaccine Industry Sales Model and Sales Channels
5.7.1 HIV Vaccine Sales Model
5.7.2 HIV Vaccine Typical Distributors

6 Sights by Product Type
6.1 HIV Vaccine Classification
6.1.1 Viral Vector Vaccines
6.1.2 Recombinant Protein Vaccines
6.1.3 Nucleic Acid Vaccines (including mRNA Vaccines)
6.1.4 Other Vaccines
6.2 by Type, Global HIV Vaccine Market Size & CAGR, 2020 VS 2024 VS 2031
6.3 by Type, Global HIV Vaccine Revenue, 2020-2031
6.4 by Type, Global HIV Vaccine Sales Volume, 2020-2031
6.5 by Type, Global HIV Vaccine Price, 2020-2031

7 Sights by Application
7.1 HIV Vaccine Segment by Application
7.1.1 Preventive Vaccine
7.1.2 Therapeutic Vaccine
7.2 by Application, Global HIV Vaccine Market Size & CAGR, 2020 VS 2024 VS 2031
7.3 by Application, Global HIV Vaccine Revenue, 2020-2031
7.4 by Application, Global HIV Vaccine Sales Volume, 2020-2031
7.5 by Application, Global HIV Vaccine Price, 2020-2031

8 Sales Sights by Region
8.1 By Region, Global HIV Vaccine Market Size, 2020 VS 2024 VS 2031
8.2 By Region, Global HIV Vaccine Revenue, 2020-2031
8.3 By Region, Global HIV Vaccine Sales Volume, 2020-2031
8.4 North America
8.4.1 North America HIV Vaccine Market Size & Forecasts, 2020-2031
8.4.2 By Country, North America HIV Vaccine Market Size Market Share
8.5 Europe
8.5.1 Europe HIV Vaccine Market Size & Forecasts, 2020-2031
8.5.2 By Country, Europe HIV Vaccine Market Size Market Share
8.6 Asia Pacific
8.6.1 Asia Pacific HIV Vaccine Market Size & Forecasts, 2020-2031
8.6.2 By Country/Region, Asia Pacific HIV Vaccine Market Size Market Share
8.7 South America
8.7.1 South AmericaHIV Vaccine Market Size & Forecasts, 2020-2031
8.7.2 By Country, South America HIV Vaccine Market Size Market Share
8.8 Middle East & Africa

9 Sales Sights by Country Level
9.1 By Country, Global HIV Vaccine Market Size & CAGR，2020 VS 2024 VS 2031
9.2 By Country, Global HIV Vaccine Revenue, 2020-2031
9.3 By Country, Global HIV Vaccine Sales Volume, 2020-2031
9.4 United States
9.4.1 United States HIV Vaccine Market Size, 2020-2031
9.4.2 By Company, United States HIV Vaccine Sales Volume Market Share, 2024
9.4.3 by Type, United States HIV Vaccine Market Size, Share, 2024 VS 2031
9.4.4 by Application, United States HIV Vaccine Market Size, Share, 2024 VS 2031
9.5 Europe
9.5.1 Europe HIV Vaccine Market Size, 2020-2031
9.5.2 By Company, Europe HIV Vaccine Sales Volume Market Share, 2024
9.5.3 by Type, Europe HIV Vaccine Market Size, Share, 2024 VS 2031
9.5.4 by Application, Europe HIV Vaccine Market Size, Share, 2024 VS 2031
9.6 China
9.6.1 China HIV Vaccine Market Size, 2020-2031
9.6.2 By Company, China HIV Vaccine Sales Volume Market Share, 2024
9.6.3 by Type, China HIV Vaccine Market Size, Share, 2024 VS 2031
9.6.4 by Application, China HIV Vaccine Market Size, Share, 2024 VS 2031
9.7 Japan
9.7.1 Japan HIV Vaccine Market Size, 2020-2031
9.7.2 By Company, Japan HIV Vaccine Market Share, 2024
9.7.3 by Type, Japan HIV Vaccine Market Size, Share, 2024 VS 2031
9.7.4 by Application, Japan HIV Vaccine Market Size, Share, 2024 VS 2031
9.8 South Korea
9.8.1 South Korea HIV Vaccine Market Size, 2020-2031
9.8.2 By Company, South Korea HIV Vaccine Market Share, 2024
9.8.3 by Type, South Korea HIV Vaccine Market Size, Share, 2024 VS 2031
9.8.4 by Application, South Korea HIV Vaccine Market Size, Share, 2024 VS 2031
9.9 Southeast Asia
9.9.1 Southeast Asia HIV Vaccine Market Size, 2020-2031
9.9.2 By Company, Southeast Asia HIV Vaccine Market Share, 2024
9.9.3 by Type, Southeast Asia HIV Vaccine Market Size, Share, 2024 VS 2031
9.9.4 by Application, Southeast Asia HIV Vaccine Market Size, Share, 2024 VS 2031
9.10 India
9.10.1 India HIV Vaccine Market Size, 2020-2031
9.10.2 By Company, India HIV Vaccine Market Share, 2024
9.10.3 by Type, India HIV Vaccine Market Size, Share, 2024 VS 2031
9.10.4 by Application, India HIV Vaccine Market Size, Share, 2024 VS 2031
9.11 Middle East & Africa
9.11.1 Middle East & Africa HIV Vaccine Market Size, 2020-2031
9.11.2 By Company, Middle East & Africa HIV Vaccine Market Share, 2024
9.11.3 by Type, Middle East & Africa HIV Vaccine Market Size, Share, 2024 VS 2031
9.11.4 by Application, Middle East & Africa HIV Vaccine Market Size, Share, 2024 VS 2031

10 Manufacturers Profile
10.1 Johnson and Johnson (Janssen)
10.1.1 Johnson and Johnson (Janssen) Company Information, Head Office, Market Area, and Industry Position
10.1.2 Johnson and Johnson (Janssen) HIV Vaccine Models, Specifications, and Application
10.1.3 Johnson and Johnson (Janssen) HIV Vaccine Sales Volume, Revenue, Price and Gross Margin, 2020-2025
10.1.4 Johnson and Johnson (Janssen) Company Profile and Main Business
10.1.5 Johnson and Johnson (Janssen) Recent Developments
10.2 Sanofi-Pasteur
10.2.1 Sanofi-Pasteur Company Information, Head Office, Market Area, and Industry Position
10.2.2 Sanofi-Pasteur HIV Vaccine Models, Specifications, and Application
10.2.3 Sanofi-Pasteur HIV Vaccine Sales Volume, Revenue, Price and Gross Margin, 2020-2025
10.2.4 Sanofi-Pasteur Company Profile and Main Business
10.2.5 Sanofi-Pasteur Recent Developments
10.3 Uvax Bio
10.3.1 Uvax Bio Company Information, Head Office, Market Area, and Industry Position
10.3.2 Uvax Bio HIV Vaccine Models, Specifications, and Application
10.3.3 Uvax Bio HIV Vaccine Sales Volume, Revenue, Price and Gross Margin, 2020-2025
10.3.4 Uvax Bio Company Profile and Main Business
10.3.5 Uvax Bio Recent Developments
10.4 AELIX Therapeutics
10.4.1 AELIX Therapeutics Company Information, Head Office, Market Area, and Industry Position
10.4.2 AELIX Therapeutics HIV Vaccine Models, Specifications, and Application
10.4.3 AELIX Therapeutics HIV Vaccine Sales Volume, Revenue, Price and Gross Margin, 2020-2025
10.4.4 AELIX Therapeutics Company Profile and Main Business
10.4.5 AELIX Therapeutics Recent Developments
10.5 IAVI
10.5.1 IAVI Company Information, Head Office, Market Area, and Industry Position
10.5.2 IAVI HIV Vaccine Models, Specifications, and Application
10.5.3 IAVI HIV Vaccine Sales Volume, Revenue, Price and Gross Margin, 2020-2025
10.5.4 IAVI Company Profile and Main Business
10.5.5 IAVI Recent Developments
10.6 HKUMed
10.6.1 HKUMed Company Information, Head Office, Market Area, and Industry Position
10.6.2 HKUMed HIV Vaccine Models, Specifications, and Application
10.6.3 HKUMed HIV Vaccine Sales Volume, Revenue, Price and Gross Margin, 2020-2025
10.6.4 HKUMed Company Profile and Main Business
10.6.5 HKUMed Recent Developments

11 Conclusion

12 Appendix
12.1 Research Methodology
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Market Estimation Model
12.4 Disclaimer

According to YH Research, the global market for HIV Vaccine should grow from US$ million in 2024 to US$ million by 2031, with a CAGR of %for the period of 2025-2031.

The strategic recalibration of 2025 U.S. tariff mechanisms is redefining global economic governance norms. This study deciphers the transmission mechanisms of tariff escalation pathways and global policy responses on corporate investment strategies, regional trade networks, and critical material supply architectures.

AIDS, or Acquired Immunodeficiency Syndrome (AIDS), is caused by the human immunodeficiency virus (HIV), also known as the AIDS virus. HIV can specifically attack and destroy human immune cells, causing damage to the human immune system, gradual loss of related immune functions, and gradually becoming the target of many diseases, leading to various serious opportunistic infections, tumors, etc. At present, AIDS has become an important public health issue that seriously threatens the health of people around the world. In 1981, doctors discovered the first known case of HIV in the United States, and since then, more than 40 million people have died from the virus. According to data from the United Nations AIDS Program, men who have sex with men, female sex workers and their clients, transgender people, and people who inject drugs are at high risk. The virus is transmitted through the exchange of body fluids of infected people, such as blood, semen, and vaginal excrement. The most common is during unprotected sex, pregnancy and childbirth, transfusion of contaminated blood, or sharing of hypodermic needles. The human body cannot completely eliminate HIV. Therefore, once infected with the virus, an individual will remain HIV positive for life. However, through antiretroviral therapy (ART) drug treatment, HIV can be controlled, its progression can be significantly slowed, and gradually become a "chronic disease". In theory, before the emergence of curative drugs, AIDS patients need to take medication for life. Although there are relatively many existing antiviral therapies, they all have a clear disadvantage: long taking cycles and short intervals. Once the medication is stopped or missed, it will lead to the deterioration of AIDS; and long-term medication may also cause problems such as drug resistance and liver damage. Historically, vaccines have been the most effective means of preventing or even eradicating infectious diseases. They can safely and cost-effectively prevent disease, disability and death. HIV vaccine is a potential vaccine that can be both a preventive vaccine and a therapeutic vaccine, meaning that it can protect individuals from HIV infection and treat HIV-infected people. In theory, it can have a significant impact on transmission rates and help control epidemics.

China HIV Vaccine market should grow from US$ million in 2024 to US$ million by 2031, with a CAGR of % for the period of 2025-2031.

The United States HIV Vaccine market should grow from US$ million in 2024 to US$ million by 2031, with a CAGR of % for the period of 2025-2031.

In terms of product type, Viral Vector Vaccines segment holds a share about % in 2024, and will reach % in 2031; while in terms of end use, Preventive Vaccine has a share approximately % in 2024, and will grow at a CAGR % during 2025 and 2031.

The global key manufacturers of HIV Vaccine include Johnson and Johnson (Janssen), Sanofi-Pasteur, Uvax Bio, AELIX Therapeutics, IAVI, HKUMed, etc. In 2024, the global top five players hold a share approximately % in terms of revenue.

This report aims to provide a comprehensive study of the global market for HIV Vaccine.
Report Highlights:
(1) Global HIV Vaccine market size (sales volume & revenue), history data from 2020-2025, and forecast data from 2026 to 2031.

(2) Global HIV Vaccine market competitive situation, sales, revenue, price, and market share, from 2020 to 2025.

(3) China HIV Vaccine market competitive situation, sales, revenue, price, and market share, from 2020 to 2025.

(4) Global HIV Vaccine segment by region (or country), key regions cover the United States, Europe, China, Japan, South Korea, Southeast Asia, and India, etc.

(5) Global HIV Vaccine segment by Type, and by Application, and regional segment by Type, and by Application.

(6) Global major production regions of HIV Vaccine, capacity, production and trends.

(7) HIV Vaccine industry supply chain, upstream, midstream, and downstream analysis.

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa
Market segment by Type, covers
Viral Vector Vaccines
Recombinant Protein Vaccines
Nucleic Acid Vaccines (including mRNA Vaccines)
Other Vaccines

Market segment by Application, can be divided into
Preventive Vaccine
Therapeutic Vaccine

Market segment by players, this report covers
Johnson and Johnson (Janssen)
Sanofi-Pasteur
Uvax Bio
AELIX Therapeutics
IAVI
HKUMed